Bryan Johnson Stops Methylene Blue and Rapamycin: What Both Experiments Reveal About Biohacking

Bryan Johnson's Blueprint: The $2M/Year Longevity Experiment

Johnson is a tech entrepreneur who sold his payment processing company Braintree to PayPal for $800 million in 2013. Rather than retiring to a beach, he pivoted his entire existence toward a single obsession: reversing his biological age. Blueprint is not a wellness program. It is, by his own description, an attempt to treat his body as a complex system that can be optimized with enough data and resources.

The $2 million funds a team of over 30 doctors and health experts who monitor every measurable aspect of his biology. He tracks body temperature, blood glucose, heart rate variability, and oxygen saturation continuously. He measures his nighttime erections (an indicator of cardiovascular health), his vocal cord aging, and his skin elasticity. He undergoes regular MRIs, full-body imaging, and blood panels that would make most physicians dizzy with data.

Every day, Johnson consumes exactly 1,977 calories of a strict vegan diet, eaten within a specific time window. He takes over 100 supplements. He follows a precise exercise regimen combining cardiovascular training with resistance work. His sleep environment is temperature-controlled to the degree, his light exposure managed to the minute.

The longevity community watches Johnson obsessively because he operates as what researchers call an n=1 clinical trial with an essentially unlimited budget. Most people who experiment with longevity compounds rely on how they feel. Johnson relies on gold-standard clinical diagnostics. When his liver function changes, he knows within days. When his epigenetic age shifts, he has the methylation data to prove it.

This is why his decisions to stop methylene blue and rapamycin reverberated through the biohacking world. These were not casual abandonments based on vibes. They were data-driven pivots backed by years of precise measurement. When the most measured human alive says a compound is not working, the theoretical mechanisms and mouse studies suddenly look a lot less convincing.

Johnson's transparency about failures is as valuable as his documentation of successes. Most wealthy biohackers experiment quietly and share only their wins. Johnson shares everything, including the interventions that cost him years of his healthspan to properly evaluate. That willingness to publish negative results is a genuine gift to anyone trying to navigate the overwhelming landscape of longevity interventions.

The Broader Lesson: Why Biohacker N=1 Experiments Matter

Johnson's meticulous self-documentation raises an important question: what can we actually learn from one person's experiments?

The scientific establishment rightly values randomized controlled trials with large sample sizes. Individual anecdotes, no matter how detailed, cannot establish causation or generalizability. Johnson's negative response to rapamycin does not mean rapamycin will fail for everyone. His interference between methylene blue and IHHT might not occur in someone with different physiology or a different protocol.

But dismissing n=1 experiments entirely misses their genuine value. Most people experimenting with longevity compounds do not document anything. They take a substance, notice (or imagine) some effect, and either continue or stop based on subjective impressions. Johnson documents everything: dosing schedules, timing, biomarkers before and after, confounding variables, and the specific reasons for discontinuation.

This level of transparency provides something the longevity community desperately lacks: detailed case studies of what happens when theoretical interventions meet actual human biology. We have plenty of mouse data showing rapamycin extends lifespan. We have very little data showing what happens when an optimized, healthy human takes it for five years with comprehensive monitoring.

Johnson's willingness to publish his failures is arguably more valuable than his successes. The supplement industry is built on cherry-picked positive results. A wealthy biohacker admitting publicly that a hyped intervention did not work, despite his best efforts to make it work, cuts through the noise in a way that cautious academic papers rarely do.

The lesson is not that Johnson's results apply universally. The lesson is that even with optimal conditions, unlimited resources, and perfect measurement, many promising longevity interventions fail to deliver. That information helps everyone make better decisions about where to invest their own time and money.

The Bryan Johnson Methylene Blue Experiment: 13 Days and Done

On August 5, 2025, Bryan Johnson posted an image that immediately captured the internet's attention. His urine had turned blue. Not slightly tinted. Genuinely, unmistakably blue.

Blue urine is the biohacking community's most glamorous side effect. It is surprisingly Instagrammable, giving the compound an aesthetic appeal that research data alone could never provide. The viral photos spread across social media, and suddenly everyone wanted to know about methylene blue.

Johnson had started experimenting with this synthetic compound, originally developed as a textile dye in 1876. Today, methylene blue remains FDA-approved for exactly one medical use: treating methemoglobinemia, a rare blood disorder where oxygen cannot be effectively delivered to tissues. Its off-label use in longevity circles centers on theoretical benefits for mitochondrial function.

Thirteen days after that viral post, he stopped taking it entirely.

The timeline reveals his meticulous approach to self-experimentation:

• May 2024: Johnson expresses public skepticism about methylene blue safety and benefits for healthy individuals.
• March 2025: Announces plans to experiment after reviewing emerging data on mitochondrial function.
• May 2025: Delays the start date to avoid confounding his other ongoing clinical experiments.
• August 5, 2025: Begins taking a daily dose of 25mg, immediately documenting the blue urine side effect.
• August 18, 2025: Stops taking the compound entirely due to severe interference with a more critical therapy.

Compare this rapid cessation to his rapamycin experiment, which lasted five years. The methylene blue trial was abandoned fast, and not because the drug directly harmed him. A higher-priority intervention was being actively disrupted by the blue dye circulating in his bloodstream. That rapid pivot tells us everything about how Johnson prioritizes: better evidence wins.

The Science Behind Methylene Blue

If your full-time job is optimizing your mitochondria, you can see why Johnson was tempted. Methylene blue functions as an electron donor in the mitochondrial respiratory chain. In theory, this allows it to bypass certain damaged steps in cellular energy production. It can potentially reduce oxidative stress and boost ATP (cellular energy) output.

The animal data is tangible, albeit modest. Laboratory worms treated with the compound showed a 10 to 14 percent lifespan extension. Female mice gained roughly a 6 percent maximum lifespan extension. Interestingly, male mice showed no significant benefit, a sex-specific discrepancy that gets ignored in most biohacking forums.

On the human side, the data is sparse. One small study involving 26 healthy adults found a 7 percent improvement in short-term memory retrieval. Most robust human research involves clinical populations facing severe cognitive decline, not healthy billionaires chasing immortality.

Proponents claim methylene blue enhances mitochondrial ATP production with up to a 15 percent boost in memory consolidation. Clinical trials extending into late 2025 are evaluating its potential for dementia prevention. But that research gap remains the elephant in the room. The mechanisms are plausible. The animal results are interesting. The human data in healthy, optimized populations is profoundly thin.

How Johnson Took Methylene Blue (and the Dangers of Aquarium Grade)

A crucial detail often glossed over is how biohackers actually consume this substance. Johnson used a highly controlled, oral dosing method. He utilized pharmaceutical-grade (USP-grade) methylene blue, carefully measured in milligram drops mixed into water. He aimed for a precise 25mg daily dose.

The distinction between pharmaceutical grade and other forms is literally a matter of life and death.

Methylene blue is widely used as a fish tank cleaner to treat fungal infections in aquariums. Many online vendors sell "aquarium grade" solutions at a fraction of the pharmaceutical price. Aquarium grade methylene blue contains heavy metal contaminants including arsenic, lead, and cadmium. Drinking fish tank cleaner in pursuit of longevity is a fast track to heavy metal poisoning, not cellular optimization.

Johnson's protocol requires pure, rigorously tested USP-grade compounds, a standard many amateur biohackers fail to meet when ordering cheap liquids online. If the price seems too good to be true, you are probably buying something designed for fish, not humans.

Why Johnson Stopped Methylene Blue

The reason Johnson halted his methylene blue experiment was not toxicity. He stopped because it created a severe operational conflict with another cornerstone of his protocol.

The conflict arose with Intermittent Hypoxia-Hyperoxia Therapy (IHHT). When he began taking methylene blue, he experienced immediate and severe hypoxia intolerance during his daily IHHT sessions. He documented crushing headaches. He noticed a massive reduction in the therapy's measured effectiveness.

There are clear biochemical reasons for this clash. Methylene blue, under hypoxic (low oxygen) conditions, can paradoxically increase reactive oxygen species. It also inhibits hypoxia-induced nitric oxide production. Nitric oxide is responsible for the vascular dilation that IHHT fundamentally depends on. By taking the blue dye, Johnson was chemically blocking the benefits of his oxygen therapy.

Johnson made a rational prioritization decision. When two longevity interventions conflict, you keep the one with stronger clinical evidence. He chose the oxygen therapy. The methylene blue experiment ended unceremoniously after 13 days.

What is IHHT and Why It Beat Methylene Blue

To understand why IHHT won, you need to understand what the therapy actually involves.

IHHT (Intermittent Hypoxia-Hyperoxia Therapy) requires breathing precisely controlled, alternating cycles of low-oxygen (hypoxic) and high-oxygen (hyperoxic) air through a specialized medical mask. Imagine climbing a massive mountain and then instantly descending to a pure oxygen bar, entirely while lying flat on a clinic bed. A typical session lasts 30 to 40 minutes and cycles between oxygen levels multiple times.

The science backing IHHT is substantial. The therapy forces the body to adapt to oxygen stress without the physical wear and tear of intense cardiovascular exercise. It enhances oxygen efficiency by increasing red blood cell count. It stimulates angiogenesis, the creation of new blood vessels. It forces weak, damaged mitochondria to die off through a process called mitophagy, replacing them with stronger, more resilient cellular powerhouses. It accelerates recovery and improves vascular health.

Johnson's calculus was straightforward. IHHT produces measurable, immediate physiological adaptations in his body. Methylene blue offers theoretical mitochondrial benefits based mostly on animal research. When one actively interfered with the other, he chose the intervention with the more robust evidence base. That decision, made in under two weeks, saved him from potentially years of experimenting with a compound that was undermining his more important protocols.

Critical Methylene Blue Safety Concerns

While Johnson's experiment ended due to a therapeutic conflict rather than direct harm, methylene blue safety concerns demand serious attention. Routine use of this compound in healthy adults bypasses the safety monitoring of clinical trials and exposes users to significant dangers.

Methylene Blue and G6PD Deficiency: A Lethal Combination

Methylene blue is absolutely contraindicated for anyone with G6PD deficiency. This genetic enzyme disorder affects nearly 5 percent of the global population, with higher prevalence in people of African, Mediterranean, and Asian descent.

Methylene blue's mechanism of action relies on NADPH. Using it in G6PD-deficient individuals rapidly depletes their already low NADPH stores. This precipitates acute, life-threatening hemolytic anemia, meaning red blood cells literally break apart and die. If you have never had a specific blood test confirming you are not G6PD deficient, taking methylene blue is gambling with your life.

Serotonin Syndrome Risk

Methylene blue is a potent, reversible monoamine oxidase A (MAO-A) inhibitor. It should never be combined with SSRIs, SNRIs, MAOIs, certain pain medications (including tramadol and meperidine), or psychiatric drugs. When mixed, it prevents the brain from breaking down serotonin. The resulting accumulation leads to serotonin syndrome, a potentially fatal condition characterized by high fever, seizures, irregular heartbeat, muscle rigidity, and unconsciousness.

Other Contraindications

• Severe kidney problems affecting drug clearance
• Pregnancy or active breastfeeding
• Any prior history of serotonin toxicity
• Concurrent use of other serotonergic medications

Both methylene blue and rapamycin require strict medical supervision. Neither should be used casually for longevity purposes without proper screening, regular monitoring, and physician oversight. RevGenetics does not sell either compound and advises against their use outside of clinical settings.

The Bryan Johnson Rapamycin Experiment: Five Years of Side Effects

If the methylene blue story is a brief sprint, the Bryan Johnson rapamycin saga is a marathon of accumulating problems.

Johnson integrated rapamycin into the Blueprint protocol and rigorously tracked its effects for five continuous years. On September 28, 2024, he publicly announced he was stopping it completely. The decision surprised many in the longevity community who considered rapamycin longevity benefits to be nearly proven.

Rapamycin is a powerful prescription immunosuppressant. It is not a vitamin. It is not a dietary supplement. It works by inhibiting the mTOR (mechanistic target of rapamycin) biological pathway. In a vast array of animal models, inhibiting mTOR extends lifespan with shocking consistency. It is the gold standard of longevity pharmacology in mice.

Johnson approached this compound with intense precision. Over five years, he documented multiple dosing schedules. He tested weekly doses ranging from 5mg to 10mg. He experimented with biweekly doses of 13mg. He tried complex alternating cycles designed to maximize benefits while minimizing side effects. Despite every optimization attempt, the clinical reality of the drug caught up with him.

The Easter Island Origins of Rapamycin

The allure of rapamycin stems partly from its almost mythical origin story.

In the 1960s, scientists collected soil samples from Easter Island (Rapa Nui), the remote Chilean territory famous for its massive stone statues. They discovered a soil bacterium that produced a compound with potent antifungal properties. They named it rapamycin after the island.

Eventually, researchers realized its true power: it suppressed the human immune system with remarkable effectiveness. The FDA approved rapamycin (sirolimus) to prevent organ transplant rejection. Patients receiving new kidneys took rapamycin so their bodies would not attack the foreign tissue.

Only much later did scientists discover that the same pathway it suppressed to prevent organ rejection, mTOR, was fundamentally linked to the cellular aging process. mTOR regulates cell growth and metabolism. When nutrients are abundant, mTOR promotes growth. When mTOR is inhibited, cells shift into a protective, maintenance mode associated with longevity.

This history is crucial context. Biohackers are taking a drug designed to stop the body from fighting off foreign organs, hoping it will stop the clock on aging. That massive biological leap requires an immense amount of faith in animal data, faith that Johnson's five years of side effects ultimately could not justify.

Rapamycin Side Effects: What Johnson Experienced

The rapamycin side effects that forced Johnson to abandon the drug were not theoretical risks read in a medical textbook. They appeared directly in his lab results and daily experience.

Recurring Skin Infections

As an immunosuppressant, rapamycin blunts the body's natural defense mechanisms. Throughout his five-year experiment, Johnson dealt with frustrating, intermittent skin and soft tissue infections. He experienced noticeably impaired wound healing. Taking a drug to improve healthspan while simultaneously suffering from persistent infections presents a miserable quality-of-life paradox.

Metabolic Disruptions

Johnson adheres to one of the most strictly optimized diets on the planet. Yet his bloodwork revealed severe metabolic disruptions. He documented elevated fasting blood glucose levels and insulin resistance. His lipid profile deteriorated, showing increased cholesterol that could elevate long-term cardiovascular risk. Developing insulin resistance while trying to live forever is a profound biological backfire.

Cardiovascular Changes

His resting heart rate actively increased during the rapamycin experiment. When your entire protocol is built on achieving the cardiovascular metrics of an elite teenager, a steadily climbing resting heart rate is a glaring red flag that demands attention.

The Scientific Literature Confirms These Effects

The medical literature aligns precisely with Johnson's struggles. Documented long-term effects of chronic mTOR inhibition include:

• Lipid disruption: Prolonged rapamycin use degrades lipid profiles, driving up bad cholesterol (PubMed 12177161).
• Insulin resistance: Multiple studies demonstrate rapamycin induces glucose intolerance and new-onset type 2 diabetes in certain populations (PMC3384435).
• Pancreatic toxicity: Credible evidence suggests rapamycin acts toxically upon pancreatic beta cells over extended timeframes (Diabetes Journal).
• NK cell inhibition: The drug suppresses natural killer cells, the body's primary defense for cancer surveillance (PMC4084728).

Breakthrough Research: Does Rapamycin Accelerate Aging?

The timing of Johnson's decision proved remarkably prescient. Just weeks after he stopped the drug, a major preprint study appeared on BioRxiv in October 2024. This research directly challenged foundational beliefs of the longevity community.

Researchers evaluated rapamycin's effects across 16 different established epigenetic aging clocks. These clocks measure biological age by analyzing DNA methylation patterns, molecular markers that change as we age. The results surprised many: rapamycin did not consistently demonstrate biological age reversal. In specific tissue models and certain clocks, the drug appeared to actively accelerate epigenetic aging markers.

Johnson noted that two specific epigenetic clocks in his own testing showed rapamycin was increasing his biological aging rate. While the October 2024 paper is a preprint (not yet peer-reviewed) and the accuracy of epigenetic clocks remains debated, the convergence of data is hard to ignore. The physiological lifespan extension seen in mice does not seamlessly map to the complex methylation patterns of human biology.

This finding does not mean rapamycin research is dead. In July 2024, the FDA approved human clinical trials led by Dr. Jonathan An at the University of Washington to test rapamycin for age-related periodontal disease. Scientists continue hunting for targeted applications. But the era of healthy biohackers taking it blindly as a longevity cure-all is facing a serious reckoning.

The Rapamycin Debate in 2025: Where Things Stand

Johnson's very public departure from rapamycin placed him at the center of an ongoing debate among longevity experts. The scientific community remains divided.

The pro-rapamycin camp: Dr. Peter Attia, one of the most influential voices in longevity medicine, continues to advocate for rapamycin's potential. He argues that dosing protocols can be optimized to minimize side effects while preserving benefits. Matt Kaeberlein, a prominent aging researcher, points to the overwhelmingly consistent mouse data as too compelling to dismiss. This camp believes the translation problem is solvable with better protocols rather than fundamental.

The skeptical camp: Nutrition scientist Chris Masterjohn offered a pointed critique supporting Johnson's move. His argument: rapamycin destroys healthspan while chasing lifespan. Extending a mouse's life at the cost of fatty liver, high blood glucose, and testicular atrophy is a terrible bargain for a human being who wants to enjoy those extra years. Johnson now aligns with this view.

The academic position: Most academic researchers take a middle ground. Rapamycin's mechanisms are well-understood and genuinely linked to aging pathways. The human data, however, remains insufficient. We have solid evidence in transplant patients who need the immunosuppression. We have very limited data in healthy people taking it purely for longevity. The few human trials underway are small and focused on specific conditions rather than general lifespan extension.

The current consensus in 2025: rapamycin remains a promising research compound, but its use by healthy individuals for longevity purposes is premature. Johnson's experience, documented over five years with a level of precision few can match, adds powerful evidence to the skeptical position. The compound may eventually find a role in human longevity, but that role likely involves more targeted applications, lower doses, or specific populations rather than broad prophylactic use.

The Bigger Pattern: What Both Experiments Reveal

Looking at both compound failures reveals a stark truth about longevity science in 2025.

The pattern is clear. Promising animal data crashes into complicated human reality. Compounds that work miracles in tightly controlled laboratory mice struggle to replicate those results in an obsessively measured human adult. Johnson's immense value to the longevity community is his transparency. He shares his failures as loudly as his successes, providing real data where most biohackers offer only anecdotes and hope.

The "Blood Boy" Experiment: Another High-Profile Failure

Johnson's willingness to abandon interventions is not new. His infamous "blood boy" experiment captured global headlines and followed the same pattern.

The concept came from parabiosis studies, where old mice surgically connected to young mice showed rapid rejuvenation. Something in young blood, researchers theorized, contained circulating factors that could reverse aging. Johnson decided to test this in himself by receiving plasma transfusions from his young son.

The media coverage was sensational. "Tech billionaire gets blood transfusions from teenage son" made for irresistible headlines. But after roughly a year of these plasma exchanges, Johnson reviewed his biomarkers. The data showed no meaningful clinical benefit. He halted the transfusions entirely.

Like rapamycin and methylene blue, the plasma experiment proved that an exciting mechanism of action means nothing without verifiable human results. The mouse parabiosis data was compelling. The human translation failed. Johnson moved on.

This pattern of aggressive experimentation followed by data-driven abandonment is what makes Johnson genuinely useful to the longevity community. He tests the interventions everyone talks about and reports honestly when they do not work. That transparency is rare and valuable in a field dominated by supplement companies selling hope and biohackers afraid to admit their expensive protocols might be useless.

Bryan Johnson Supplement Stack 2025: What He Actually Takes Now

The Bryan Johnson supplement stack 2025 shows a distinct shift away from experimental pharmaceuticals and toward metabolic foundations.

After dropping rapamycin and methylene blue, Johnson adjusted his core regimen. He lowered his dose of metformin. He pivoted heavily into a new intensive Hyperbaric Oxygen Therapy (HBOT) protocol starting in late 2024. He doubled down on his famous "Nutty Pudding," a precise blend of macadamia nuts, walnuts, berries, and specific polyphenols he consumes daily.

His current approach emphasizes:

• Sleep optimization: Temperature-controlled mattresses, strict light exposure management, and consistent sleep/wake times to maximize deep sleep phases.
• Precise nutrition: Exactly 1,977 calories daily of a vegan diet eaten within specific time windows. Every macronutrient measured and optimized.
• Combined exercise: Cardiovascular training and resistance work, carefully programmed to avoid overtraining while maximizing adaptation.
• NAD+ support: Continued supplementation with NAD+ precursors rather than experimental drugs.
• Oxygen therapies: Both IHHT (which beat methylene blue) and HBOT remain in his protocol.

The cutting edge of biohacking in 2025 looks surprisingly foundational. It is less about magic pills and more about the relentless execution of perfect daily habits. Johnson's experiments with rapamycin and methylene blue taught him (and those watching) that flashy compounds cannot compensate for boring consistency.

What Actually Works: Evidence-Based Longevity Approaches

Johnson's shift away from experimental pharmaceuticals aligns with a core philosophy at RevGenetics. The longevity market overflows with theoretical mechanisms. It starves for robust human data.

Rather than inhibiting critical pathways with harsh drugs like rapamycin, activating natural cellular defenses offers a safer path. Activating the AMPK and SIRT1 pathways using naturally derived compounds mimics the beneficial stress of fasting and exercise, without immunosuppressive nightmares.

Supplementation with Meaningful Human Evidence

The compounds that actually possess strong human evidence for supporting healthy cellular aging are accessible, legal, and extensively tested:

• NMN (Nicotinamide Mononucleotide): A 2024 meta-analysis of 12 randomized controlled trials confirmed NMN significantly improves glucose and lipid metabolism in adults. The FDA confirmed NMN's legal status as a dietary supplement in September 2025. Explore RevGenetics Advanced NMN 1000, enteric-coated and third-party verified to deliver exactly 1,029mg.
• Resveratrol: A rigorous March 2025 GRADE-assessed systematic review of human RCTs confirmed resveratrol effectively activates SIRT1, reduces blood pressure, and improves lipid profiles without toxic side effects. Review RevGenetics 99% pure trans-resveratrol.
• Spermidine: Multiple human clinical trials showcase its promise for supporting cognitive health and cardiovascular function through the induction of natural autophagy. See RevGenetics wheat-free Rapymine.
• TA-65 (Cycloastragenol): A 2025 meta-analysis spanning 8 randomized controlled trials with over 750 participants confirmed statistically significant telomere lengthening in humans. Discover RevGenetics TA-65 Telomerase Activator.

None of these compounds require a doctor to suppress your immune system. None carry the risk of severe serotonin syndrome. All are backed by real human trial data demonstrating safety and efficacy.